Recce Pharmaceuticals Secures Key Brazilian Patent for Anti-Infective Platform

Recce Pharmaceuticals' receipt of a patent grant from Brazil’s National Institute of Industrial Property (INPI) represents a strategic milestone in the company’s global intellectual property (IP) strategy. By securing protection in Brazil, the largest economy in Latin America, Recce is positioning its synthetic anti-infective platform to address one of the most pressing challenges in modern medicine: antimicrobial resistance (AMR). This grant specifically covers the composition of matter and preparation methods for its core technology, providing a legal moat in a region where healthcare infrastructure is increasingly strained by drug-resistant 'superbugs.'

The global anti-infective market is undergoing a paradigm shift. Traditional antibiotics are failing, and the regulatory environment is pivoting toward incentivizing non-traditional anti-infectives. Recce’s platform differs from traditional antibiotics because it is synthetic and designed to maintain efficacy even after repeated use, a feature that is particularly attractive to regulators like the FDA and now the INPI. Brazil, with its population of over 215 million, represents a high-burden environment for infectious diseases, making it a critical territory for clinical and commercial expansion. The patent, titled 'Anti-Infective Agents and Method for Their Preparation,' covers the unique chemical structure of Recce's polymers, which are designed to physically disrupt the cell walls of bacteria while remaining safe for human cells.

“

Recce Pharmaceuticals' receipt of a patent grant from Brazil’s National Institute of Industrial Property (INPI) represents a strategic milestone in the company’s global intellectual property (IP) strategy.

For Legal and RegTech professionals, this development highlights the importance of multi-jurisdictional IP filings in the biotech sector. Brazil has historically been a challenging jurisdiction for pharmaceutical patents due to a significant backlog and rigorous examination processes. Recce’s success here suggests a robust patent application that meets high standards of novelty and industrial applicability. This grant not only protects Recce's current pipeline but also increases the company's valuation for potential licensing deals or acquisitions by larger pharmaceutical entities looking to bolster their anti-infective portfolios. The mechanism of action for RECCE® 327 is particularly noteworthy; unlike traditional antibiotics that target specific metabolic pathways, Recce’s synthetic polymers employ a physical mode of action that makes it significantly harder for bacteria to develop resistance.